<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1292</article-id>
      <article-id pub-id-type="doi">10.51847/SZ1ZvPQgAj</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Can Artificial Intelligence Distinguish Helpful Complexity from Harmful Polypharmacy? A Critical Evidence Review</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>El Idrissi</surname>
                <given-names>Fatima</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Bennani</surname>
                <given-names>Samira</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Benali</surname>
                <given-names>Youssef</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Ben Ali</surname>
                <given-names>Ahmed</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of AI and Polypharmacy Assessment, Faculty of Pharmacy, University of Marrakech, Marrakech, Morocco.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Helpful vs. Harmful Complexity, Faculty of Pharmacy, University of Fez, Fez, Morocco.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Clinical Pharmacy and AI Review, Faculty of Pharmacy, University of Casablanca, Casablanca, Morocco.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="fatima.idrissi@uca.ma">fatima.idrissi@uca.ma</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>16</day>
        <month>08</month>
        <year>2026</year>
      </pub-date>
      <volume>17</volume>
      <issue>3</issue>
      <fpage>36</fpage>
      <lpage>45</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Polypharmacy may represent necessary treatment for multimorbidity or expose patients to avoidable harm. Artificial intelligence is proposed to identify inappropriate medicines, predict interactions, and support deprescribing, but model accuracy does not establish whether a regimen’s complexity is beneficial or harmful. To critically examine whether current systems distinguish helpful medication complexity from harmful polypharmacy, and to identify the evidence required for that claim. A bounded critical evidence review used seven frozen Google Scholar searches, supplementary citation searching, and publisher, PubMed, and Crossref verification. Of 104 captured records, 28 duplicates were removed, 76 were screened, 45 reports were sought, 43 were assessed, and 21 reports representing 21 studies or reviews were included. Evidence was extracted by construct, target, reference standard, validation design, patient context, clinical utility, and risk of inappropriate simplification. Prediction studies, interventions, reviews, and contextual studies were appraised using appropriate domains and synthesized without pooling. Most systems predicted criteria-defined potentially inappropriate medication labels, compiled rule-based warnings, estimated interaction or hospitalization risk, or generated clinician-mediated deprescribing suggestions. Prospective systems could increase discontinuation or reduce medication burden, yet clinical-outcome findings were limited and mixed. Patient goals, prognosis, indication, time-to-benefit, and treatment burden were rarely represented directly. Proxy-label circularity, restricted external validation, and outcome disconnect limited interpretation. Current evidence supports artificial intelligence as a source of partial medication-risk signals, not as a demonstrated judge of patient-specific regimen value. Distinguishing helpful complexity from harm requires explicit benefit representation, contextual goals, counterfactual comparison, prospective evaluation, human adjudication, and safety monitoring.</p>
      </abstract>
      <kwd-group>
                <kwd>Critical evidence review</kwd>
                <kwd>Digital pharmacy</kwd>
                <kwd>Artificial intelligence</kwd>
                <kwd>Pharmacy practice</kwd>
                <kwd>Medication safety</kwd>
                <kwd>Evidence synthesis</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>